A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
WU-CART-007 is an investigational anti-CD7 CAR-T cell therapy for relapsed or refractory T-ALL/LBL, derived from healthy donor T cells to avoid malignant contamination. The phase 2 trial aims to ...
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...
A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
CAR-T cell therapy faces accessibility challenges, primarily available at large urban centers, leading to geographic and socioeconomic disparities. The KarMMa-3 study showed Abecma CAR-T therapy ...
Patient Glioblastoma Response to CAR-T Cell Therapy Mirrored in Tumor-Derived Organoids in Real Time
Researchers at the Perelman School of Medicine at the University of Pennsylvania have for the first time used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to ...
In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...
Please provide your email address to receive an email when new articles are posted on . Patients who would not have been eligible for pivotal CAR-T trials may still derive benefit from the therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results